Acer Therapeutics Stock Cash Flow From Operations
| ACERDelisted Stock | USD 0.84 0.02 2.33% |
Acer Therapeutics fundamentals help investors to digest information that contributes to Acer Therapeutics' financial success or failures. It also enables traders to predict the movement of Acer Stock. The fundamental analysis module provides a way to measure Acer Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acer Therapeutics stock.
Acer |
Acer Therapeutics Company Cash Flow From Operations Analysis
Acer Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Acer Therapeutics Cash Flow From Operations | (30.25 M) |
Most of Acer Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acer Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Acer Therapeutics has (30.25 Million) in Cash Flow From Operations. This is 105.74% lower than that of the Pharmaceuticals sector and 148.38% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 103.11% higher than that of the company.
Acer Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acer Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acer Therapeutics could also be used in its relative valuation, which is a method of valuing Acer Therapeutics by comparing valuation metrics of similar companies.Acer Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Acer Fundamentals
| Return On Equity | -4.73 | |||
| Return On Asset | -0.65 | |||
| Current Valuation | 52.01 M | |||
| Shares Outstanding | 24.46 M | |||
| Shares Owned By Insiders | 13.78 % | |||
| Shares Owned By Institutions | 29.91 % | |||
| Number Of Shares Shorted | 493.55 K | |||
| Price To Earning | (7.40) X | |||
| Price To Book | 17.26 X | |||
| Price To Sales | 174.52 X | |||
| Gross Profit | 1.26 M | |||
| EBITDA | (24.81 M) | |||
| Net Income | (26.24 M) | |||
| Cash And Equivalents | 14.47 M | |||
| Cash Per Share | 0.91 X | |||
| Total Debt | 11.86 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 0.87 X | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (30.25 M) | |||
| Short Ratio | 2.87 X | |||
| Earnings Per Share | (1.98) X | |||
| Target Price | 1.5 | |||
| Number Of Employees | 30 | |||
| Beta | 0.44 | |||
| Market Capitalization | 22.02 M | |||
| Total Asset | 11.62 M | |||
| Retained Earnings | (140.75 M) | |||
| Working Capital | (15.44 M) | |||
| Current Asset | 6.61 M | |||
| Current Liabilities | 5.62 M | |||
| Z Score | -24.48 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 11.62 M |
About Acer Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acer Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acer Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acer Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Acer Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acer Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acer Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Acer Stock
| 0.53 | MMM | 3M Company Fiscal Year End 28th of January 2025 | PairCorr |
| 0.42 | GE | GE Aerospace Fiscal Year End 28th of January 2025 | PairCorr |
| 0.37 | HD | Home Depot | PairCorr |
| 0.34 | VZ | Verizon Communications Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Acer Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acer Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acer Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acer Therapeutics to buy it.
The correlation of Acer Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acer Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acer Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acer Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Acer Stock
If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |